管炎灵颗粒治疗胃热气滞型非糜烂性胃食管反流病的临床研究

摘要
图/表
参考文献(24)
相关文章 (0)

全文: PDF (460 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究管炎灵颗粒治疗胃热气滞型非糜烂性胃食管反流病（NERD）的临床效果。方法选取2015年1月～2017年1月江苏省盐城市中医院收治的胃热气滞型NERD患者86例，依据随机数字表法将其分为观察组和对照组，各43例。对照组采用奥美拉唑胶囊治疗，观察组在对照组的基础上采用管炎灵颗粒治疗。两组患者均治疗4周。观察两组患者中医证候的治疗效果、反流性疾病问卷（RDQ）积分变化情况、临床症状（反流、胃脘闷胀、口干口苦、咽部异物感、胸闷胸痛、心烦易怒和烧心）积分、不良反应和血清脑肠肽激素Ghrelin、脂质过氧化物（LPO）水平。结果治疗后两组患者RDQ积分均较治疗前显著降低，且观察组RDQ积分显著低于对照组，差异有统计学意义（P ＜ 0.05）。观察组和对照组的中医证候总有效率分别为86.05%、55.81%，差异有统计学意义（P ＜ 0.05）。两组血清Ghrelin水平均较治疗前明显上升，LPO水平均较治疗前明显下降，差异有统计学意义（P ＜ 0.05）。治疗后观察组各项临床症状积分均较治疗前明显下降（P ＜ 0.05），除口干口苦外，其他症状积分与对照组比较差异均有统计学意义（P ＜ 0.05）。观察组有2例患者发生轻微腹泻，对照组有3例患者发生腹胀。结论管炎灵颗粒治疗NERD患者效果显著，无明显不良反应，值得临床关注。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄河黄福斌张阳刘柱成仇玕

关键词 ：管炎灵颗粒, 非糜烂性胃食管反流病, 胃热气滞型

Abstract：Objective To study the clinical efficacy of Guan Yanling Granules in the treatment of non-erosive reflux disease (NERD) with syndrome of stomach heat and qi stagnation. Methods Eighty-six NERD patients with syndrome of stomach heat and qi stagnation admitted to Yancheng Hospital of Traditional Chinese Medicine from January 2015 to January 2017 were selected. According to the random number table method, the patients were divided into the observation group and the control group, with 43 cases in each group. The control group was treated with Omeprazole Capsules, and the observation group was treated with Guan Yanling Granules on basis of the control group. Both groups were treated for 4 weeks. The treatment effect of TCM symptoms, changes in the scores of reflux disease questionnaires, scores of clinical symptoms (regurgitation, fullness of gastral cavity, dry and bitter taste, paraesthesia pharynges, chest distress and chest pain, annoyance and irritability, heartburn), adverse reactions, and the levels of serum Ghrelin and lipid peroxide (LPO) in the two groups were observed. Results After treatment, the RDQ scores of the two groups were significantly lower than those before treatment, and the RDQ scores of the observation group were significantly lower than those of the control group, the difference was statistically significant (P ＜ 0.05). The total effective rates of TCM symptoms in the observation group and the control group were 86.05% and 55.81%, the difference was statistically significant (P ＜ 0.05). The serum Ghrelin levels of the two groups were significantly higher than those before treatment, and the levels of LPO were significantly lower than those before treatment, the differences were statistically significant (P ＜ 0.05). After treatment, the scores of clinical symptoms in the observation group were significantly lower than those before treatment, the differences were statistically significant (P ＜ 0.05), in addition to dry and bitter taste, the other symptoms in the observation group had statistically significant differences compared with those of control group (P ＜ 0.05). In the observation group, 2 cases had slight diarrhea, and 3 cases in the control group suffered from abdominal distention. Conclusion Guan Yanling Granules in the treatment of patients with NERD has significant effects and no obvious adverse reactions, which is worthy of clinical attention.

Key words： Guan Yanling Granules Non-erosive reflux disease Syndrome of stomach heat and qi stagnation

基金资助:江苏省中医药科技项目（YB2015130）。

引用本文:

黄河黄福斌张阳刘柱成仇玕. 管炎灵颗粒治疗胃热气滞型非糜烂性胃食管反流病的临床研究[J]. 中国医药导报, 2017, 14(30): 139-142.
HUANG He HUANG Fubin ZHANG Yang LIU Zhucheng QIU Gan. Clinical study of Guan Yanling Granules in the treatment of non-erosive reflux disease with syndrome of stomach heat and qi stagnation. 中国医药导报, 2017, 14(30): 139-142.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I30/139

[1] 刘恋.奥美拉唑联合氟哌噻吨美利曲辛治疗中重度非糜烂性胃食管反流病疗效[J].中国医药科学，2016，6（15）：77-79.
[2] 童诚，徐康.雷贝拉唑钠肠溶片对非糜烂性胃食管反流病患者反流次数及血清LPO的影响[J].南通大学学报：医学版，2016，36（6）：620-622.
[3] Yang Y，Emergency DO，Hospital BC. Clinical applicant of flupentixol and melitracen in non-erosive gastro-esophageal reflux disease complicated with anxiety or depression [J]. Int J Digest Dis，2016，19（4）：184-189.
[4] 沈雯雯，张玫.枳术宽中胶囊联合质子泵抑制剂和氟哌噻吨美利曲辛治疗非糜烂性胃食管反流病42例[J].河南中医，2015，35（9）：2153-2155.
[5] 林三仁，许国铭，胡品津，等.中国胃食管反流病共识意见（2006·10三亚）[J].中华内科杂志，2007，46（2）：170-173.
[6] 李乾构，周学文，单兆伟.实用中医消化病学[M].北京：人民卫生出版社，2004.
[7] 张慧茹，王亚雷，许建明.反流性疾病问卷对胃食管反流病的诊断价值[J].安徽医药，2009，13（6）：637-639.
[8] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[9] 王连山.中医辨证治疗非糜烂性胃食管流病46例临床观察[J].医药前沿，2015，206（18）：304-305.
[10] 许芸斐，黄君兰.中西医结合治疗肝胃郁热型非糜烂性胃食管反流病53例临床研究[J].临床医学研究与实践，2016，1（14）：103-104.
[11] Silva RO，Oliveira FF，Bingana RD，et al. A novel murine model of esophageal non-erosive reflux disease（NERD）：From inflammation to impairment in mucosal integrity [J]. Am J Physiol Gastrointest Liver Physiol，2017，19（6）：19-24.
[12] Sugimoto M，Uotani T，Ichikawa H，et al. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan [J]. Digestion，2016，93（1）：24-29.
[13] 金丽杰.自拟降逆健胃方治疗非糜烂性胃食管反流病临床观察[J].北京中医药，2015，44（7）：566-568.
[14] Yamashita H，Ashida K，Kawaguchi S，et al. The pathogenesis of persistent non-erosive reflux disease treated with proton-pump inhibitors as measured with the Symptom Index [J]. Esophagus，2015，12（1）：50-56.
[15] 杨娜.非糜烂性胃食管反流病中医辨证治疗临床探讨[J].中国实用医药，2015，9（2）：113-114.
[16] 杨勇.氟哌噻吨美利曲辛在伴有焦虑或抑郁的非糜烂性胃食管反流病中的临床应用[J].国际消化病杂志，2016， 36（5）：287-290.
[17] 刘玉梅.中药改善非糜烂性胃食管反流80例疗效观察[J].北华大学学报：自然，2015，16（4）：508-511.
[18] 张秀莲，朱生樑，刘春芳，等.疏肝和胃方改善非糜烂性胃食管反流病主要症状的临床观察[J].中华中医药杂志，2015，7（2）：622-625.
[19] 戴高中，田秋实，范先靖，等.疏肝宁神降逆护膜方对非糜烂性反流病患者CGRP、SP含量的影响[J].南京中医药大学学报，2016，32（6）：519-523.
[20] 国华，杨土英，林红，等.雷贝拉唑与雷尼替丁在非糜烂性胃食管反流病中的疗效与安全性比较[J].中国现代医生，2017，55（3）：30-32，36.
[21] 魏冬梅.柴胡疏肝散联合西药治疗非糜烂性反流性食管炎95例[J].陕西中医学院学报，2015，3（2）：174-179.
[22] Yamamoto SR，Yano F，Omura N，et al. Efficacy of laparoscopic Toupet fundoplication for non-erosive reflux disease assessed by combined multichannel intraluminal impedance-pH monitoring [J]. Esophagus，2015，12（3）：219-224.
[23] 王文婷，张厂，王林恒，等.胃食管反流病中医证候学研究探索[J].环球中医药，2016，9（8）：931-936.
[24] Kusano M，Hosaka H，Kawamura O，et al. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy [J]. J Gastroenterol，2015，50（3）：298-304.